Beyond science, built for real life

Our vision

We believe successful healthcare innovation must not only be scientifically sound, but also strategically designed to meet evolving market needs, support healthcare professionals, and create lasting differentiation for our partners worldwide.

We combine advanced scientific expertise, applied research, and industrial vision to create ready-to-market products for global partners seeking concrete, reliable, and differentiated innovation.

 

Our mission

Our approach goes beyond product development alone: we work to transform scientific innovation into commercially sustainable opportunities, building solutions that can generate real value in increasingly competitive healthcare markets.

By integrating research, regulatory strategy, production, branding, and market positioning into a single development process, we help partners accelerate time-to-market while strengthening product identity and long-term commercial potential.

Our journey

2015
Milan
Foundation of Metis Healthcare
2016
Agreement with the University of Milan

for the exclusive use of the MIMHL5 strain, isolated and characterized by Prof. Simone Guglielmetti

2016
Patent on oral preparation comtaining lactobacilluls helveticusn
2020
Publication of the first clinical study on Salifluss efficacy
2020
Golabact launch in Italy
2020
Publication of the first clinical trial on Golabact efficacy
2021
Publication of the second clinical study on Salifluss efficacy
2021
Patent: technology to improve dental plaque
2022
Golabact launch in Ukraine by Valartin
2022
Salifluss technology patent granted in USA and Europe
2022
Pirocalm launch in Spain by Atika Pharma
2022
Golabact launch in the Balkan region as Tonzilette by Bonifar
2023
Salifluss launch in Norway and Sweden by Novus Dental
2024
Publication of the first clinical trial on Golabact efficacy
2024
Development of the Salifluss line extension: Foam and Mouthwash
2024
Beginning of the Metis Healthcare rebranding project
2025
Golabact launch in the Emirates by Pharma Access
2025
Agreement with Molteni Farma

for the launch of Salifluss in Italy under the brand Idroral, for the treatment of chemotherapy-induced xerostomia

2025
Salifluss launch in Great Britain by Kora Pharma
2025
Salifluss launch in Cyprus by Golgi Pharma
2025
Trifar Pharma acquires 25% of Metis Healthcare
2025
Salifluss launch in Italy by Metis Healthcare in the oral care market